摘要
目的 评价拓扑替康联合顺铂治疗小细胞肺癌 (SCLC)的疗效及安全性。方法 经病理组织学或细胞学确诊的 19例 ,用药方法为拓扑替康 (Topotecan ,TPT) 1.0mg/ (m2 ·d) ,静滴 30分钟 ,连用 5天 ;顺铂 (Cisplatin ,DDP) 30mg/m2 静滴 ,连用 3天 ,每 3周一疗程。治疗 2疗程评价疗效。结果 19例可评价病人。总有效率为 4 7.6 % ,对初治及复治SCLC的有效率分别为 6 6 .7%、38.5 %。主要毒副反应为骨髓抑制。Ⅲ～Ⅳ度中性粒细胞减少及血小板减少的发生率分别为 5 2 .6 %、4 2 .1%。贫血发生率为6 3.5 % ,其中 2 6 .3%为中重度贫血。非血液学毒性较轻 ,一般可耐受。结论 拓扑替康联合顺铂为治疗SCLC的有效化疗方案 ,特别对复发的病例疗效较好。主要毒性为骨髓抑制 ,用药时应予足够重视。
Objective To evaluate the efficacy and safty of combined topotecan(TPT) with cisplatin(DDP) in the treatment of small-cell lung cancer(SCLC). Methods 19 patients with SCLC diagnosed by pathology or cytology were enrolled into the study. The patients were treated with TPT[ 1.0mg/(m2·d) intravenously(IV) during 30 minutes on d 1～5 and DDP (30mg/m2 IV on d 1～3) of 3-week regiment. The efficacy was evaluated after 2 cycles of treatment. Results 19 of all the cases could be evaluated. The total response rate was 47.6%. Response rate of this regiment as first line and as second line chemotherapy was 66.7% and 38.5% respectively. Myelosuppression was the main toxicity. Grade Ⅲ～Ⅳ neutropenia and thrombopenia was observed in 52.6% and 42.1% respectively. Anemia was found in 63.5% patients, 26.3% of them experienced grade Ⅲ or Ⅳ anemia. Non-hemotological toxicity was mild and tolerable.Conclusion The combination of topotecan and cisplatin is an effective regiment in the treatment of SCLC, especially of recurrent SCLC. The major toxicity is myelosuppression and should be taken seriously.
出处
《肿瘤防治研究》
CAS
CSCD
2004年第12期776-778,共3页
Cancer Research on Prevention and Treatment
关键词
小细胞肺癌
拓扑替康
顺铂
疗效
毒性
Small-cell lung cancer
Topotecan
Cisplatin
Efficacy
Toxicity
